Clinical Trial Update: Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 clinical trial evaluating intravenous estramustine in combination with paclitaxel (Taxol) for hormone-refractory prostate adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Estramustine (estramustine)
• Taxol (paclitaxel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED